Catabasis Pharmaceuticals, Inc.

Catabasis Pharmaceuticals, Inc.

Catabasis Pharmaceuticals, Inc.

Overview
Date Founded

2008

Headquarters

One Kendall Square,Building 1400 East,Suite B14202,Cambridge, MA 02139

Type of Company

Public

Employees (Worldwide)

24

Industries

Pharmaceuticals
Hospitals & Patient Services
Medical Support Services
Biotechnology

Company Description

Catabasis Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is edasalonexent, which is intended for the treatment of Duchenne muscular dystrophy. The company was founded by Michael R. Jirousek, Jill C. Milne, and Steven E. Shoelson on June 26, 2008 and is headquartered in Cambridge, MA.

Contact Data
Trying to get in touch with decision makers at Catabasis Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder

Chief Legal Officer

Chief Scientific Officer

Chief Medical Officer & Senior Vice President-Clinical Development

Vice President, Finance & Principal Accounting Officer

Senior Vice President, Product Development

Vice President, Corporate Affairs

Vice President, Regulatory Affairs

Director of Pharmacology

Director

Board of Directors

Professional at Epizyme, Inc.

Co-Founder at Cerium Pharmaceuticals, Inc.

Executive Vice President, Pharmaceutical Development & Operations at Celgene Corp.

Co-Founder at Verve Therapeutics, Inc.

Professional at Catabasis Pharmaceuticals, Inc.

Co-Founder at Catabasis Pharmaceuticals, Inc.

Professional at Alinea Pharmaceuticals, Inc.

Paths to Catabasis Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Catabasis Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

Stonepine Capital Management focuses primarily, but not exclusively, on equity and equity-related securities in US publicly healthcare companies. The firm seeks to invest in companies whose valuations reflect a material discount to their fundamental value in the healthcare space. Stonepine typically prefers to invest in companies at a price reflecting a discount to current commercial and financial assets alone.The Stonepine Funds' investment objective is to achieve superior absolute returns while preserving capital. They have formed Special Purpose Vehicles (SPVs) whose investment objective may differ because these investments tend to be more concentrated than the Stonepine Funds. Stonepine seeks to achieve their investment objective primarily by investing assets in publicly traded healthcare companies. Stonepine's investment focus is companies with commercial stage products generating sustainable revenue and companies with substantial financial assets (such as cash and royalty income streams).

Details Hidden

Stonepine Capital Management focuses primarily, but not exclusively, on equity and equity-related securities in US publicly healthcare companies. The firm seeks to invest in companies whose valuations reflect a material discount to their fundamental value in the healthcare space. Stonepine typically prefers to invest in companies at a price reflecting a discount to current commercial and financial assets alone.The Stonepine Funds' investment objective is to achieve superior absolute returns while preserving capital. They have formed Special Purpose Vehicles (SPVs) whose investment objective may differ because these investments tend to be more concentrated than the Stonepine Funds. Stonepine seeks to achieve their investment objective primarily by investing assets in publicly traded healthcare companies. Stonepine's investment focus is companies with commercial stage products generating sustainable revenue and companies with substantial financial assets (such as cash and royalty income streams).

Details Hidden

Empery Asset Management manages an event-driven, special situations fund that invests in small- to mid-sized growth companies. They make direct investments in US publicly-traded companies without respect to industry, although some of the companies are based in China.

Recent Transactions
Details Hidden

Catabasis Pharmaceuticals, Inc. issued USD Units Consisting of Common Stock and Warrants

Details Hidden

Catabasis Pharmaceuticals, Inc. issued USD Units Consisting of Common Stock and Warrants

Details Hidden

Catabasis Pharmaceuticals, Inc. issued USD Common Stock

Transaction Advisors
Escrow Agent

Advised onCatabasis Pharmaceuticals, Inc. issued Common Stock

Legal Advisor

Advised onCatabasis Pharmaceuticals, Inc. issued USD Units Consisting of Common Stock and Warrants

Underwriter

Advised onCatabasis Pharmaceuticals, Inc. issued Common Stock

Legal Advisor

Advised onCatabasis Pharmaceuticals, Inc. issued USD Units Consisting of Common Stock and Warrants

Managing Director

Advised onCatabasis Pharmaceuticals, Inc. issued USD Units Consisting of Common Stock and Warrants

Counsel

Advised onCatabasis Pharmaceuticals, Inc. issued USD Units Consisting of Common Stock and Warrants

Advisors & Consultants
Legal Advisor

Co-Chair, Corporate Practice Group at Wilmer Cutler Pickering Hale and Dorr LLP

Advisor

Chief Financial Officer at Boston Pharmaceuticals

Key Stats and Financials As of 2018
Market Capitalization
$93.1M
Total Enterprise Value
$-15.5M
Earnings Per Share
$-5.12
Revenue
$0
Net Profit
$-25.9M
EBITDA
$-25.4M
Total Debt
$0
Total Equity
$34.9M
TEVNet Income
0.6x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
0%
Five Year Compounded Annual Growth Rate Of Revenue
0%
Investors
Details Hidden

Founded in 1993, SV Health Investors LLC is a venture capital firm headquartered in Boston. The firm is a subsidiary of SV Life Sciences Advisers LLP, a venture capital investment firm based in London. SV Health Investors was formerly known as Schroder Ventures Life Sciences. They advise and manage several venture capital funds for corporate clients and private individuals.

Details Hidden

Clarus Ventures focuses on investments in the life science industry. The firm's invests primarily in biopharmaceutical and medical technology companies. Clarus Ventures has particular expertise in research and development, commercialization, business development and operations management at the global level. The firm also makes investment in public company.

Details Hidden

MedImmune Ventures focuses on discovering, developing and commercializing promising developments in the biotechnology products sector. The firm targets investments in areas with strategic potential for MedImmune LLC and AstraZeneca including: (1) cardiovascular disease (2) gastrointestinal disease (3) neuroscience (4) oncology (5) infectious diseases (6) respiratory disease and (7) inflammation.MedImmune Ventures invests in early- to late-stage, public or private biotechnology companies that discover and develop human therapeutics. They place particular emphasis on the fields of infectious disease, immunology and oncology. Their Funds are modality agnostic, investing in biologics, small molecules and vaccines. Investments range up to $30 million per company with average investments of about $7 million.

Competitors
Pfizer, Inc. Pharmaceuticals - New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Roche Holding AG Pharmaceuticals - Basel, BS

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

FibroGen, Inc. Biotechnology - SAN FRANCISCO, CA

FibroGen, Inc. engages in the discovery, development, and commercialization of therapeutics. It focuses on hypoxia-inducible factor and connective tissue growth factor biology to develop innovative medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Catabasis Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Catabasis Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Catabasis Pharmaceuticals, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/catabasis-pharmaceuticals-inc-202709
  • https://relationshipscience.com/organization/catabasis-pharmaceuticals-inc-202709